Subgroups Receiving Intensified Therapy Directed to the CNS
| CSF Finding* . | No. of Patients . | No. of Intrathecal Treatments . | Dose of Cranial Irradiation (cGy) . | |
|---|---|---|---|---|
| First 12 wks . | Total . | |||
| Lower risk | ||||
| CNS-1 | 89 | 6 | 13 | 0 |
| CNS-2 | 27 | 8 | 21 | 0 |
| Contaminated | 12 | 8 | 21 | 0 |
| Higher risk-151 | ||||
| CNS-1 | 12 | 6 | 24 | 1,800 |
| CNS-2 | 15 | 8 | 26 | 1,800 |
| Contaminated | 4 | 8 | 26 | 1,800 |
| CNS-3 | 6 | 8 | 26 | 2,400 |
| CSF Finding* . | No. of Patients . | No. of Intrathecal Treatments . | Dose of Cranial Irradiation (cGy) . | |
|---|---|---|---|---|
| First 12 wks . | Total . | |||
| Lower risk | ||||
| CNS-1 | 89 | 6 | 13 | 0 |
| CNS-2 | 27 | 8 | 21 | 0 |
| Contaminated | 12 | 8 | 21 | 0 |
| Higher risk-151 | ||||
| CNS-1 | 12 | 6 | 24 | 1,800 |
| CNS-2 | 15 | 8 | 26 | 1,800 |
| Contaminated | 4 | 8 | 26 | 1,800 |
| CNS-3 | 6 | 8 | 26 | 2,400 |
*CNS-1 status is defined by no identifiable blast cells in CSF; CNS-2, fewer than 5 leukocytes/μL with definable blast cells in CSF; CNS-3, 5 or more leukocytes/μL with definable blast cells in CSF or the presence of cranial nerve palsy; andcontaminated, more than 10 erythrocytes/μL with detectable blast cells in CSF.
B-cell precursor phenotype with a leukocyte count of at least 100 × 109/L, a T-cell phenotype with a leukocyte count of at least 50 × 109/L, or a karyotype with the Philadelphia chromosome. All other cases were considered lower risk.